Molecular Mechanisms and Therapies of Myeloid Leukaemia
Approach | Targets |
---|---|
Adoptive T cell therapy | CAR-T cells [20], CD44v6 CAR-T cells [21], FLT-3 CAR-T cells [22], CLL1/CD33 CAR-T cells [23] |
Adoptive NK cell therapy | Infusion of haploidentical NK cells [24] and NK cell activation [25]. |
T cell engagers | Bispecific antibodies targeting CD33, tandem diabodies IL-3 and CD123 [26], BiTes and BiKes [27], dual affinity retargeting antibodies [28]. |
Checkpoint blockade and macrophage checkpoint blockade | PD-1 inhibitor [29], TIM-3 [30], CD47 [31]. |
mAbs | CD33, CD123, CD16, CD38, CD47, CD25 [32]. |
Vaccines | Boost immunity and provoke a response [33], Wilms’ tumour 1 (WT1) [34], P3 peptide vaccination [35]. |
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
AML | Acute myeloid leukaemia |
BM | Bone marrow |
CAR | Chimeric antigen receptor |
HSCT | Haematopoietic stem cell transplantation |
IDH | isocitrate dehydrogenase |
mAbs | monoclonal antibodies |
References
- Shallis, R.M.; Wang, R.; Davidoff, A.; Ma, X.; Zeidan, A.M. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019, 36, 70–87. [Google Scholar] [CrossRef] [PubMed]
- Creutzig, U.; Kutny, M.A.; Barr, R.; Schlenk, R.F.; Ribeiro, R.C. Acute myelogenous leukemia in adolescents and young adults. Pediatr. Blood Cancer 2018, 65, e27089. [Google Scholar] [CrossRef] [PubMed]
- Hao, T.; Li-Talley, M.; Buck, A.; Chen, W. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci. Rep. 2019, 9, 12070. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cancer Research UK. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-aml/incidence#heading-One (accessed on 19 May 2022).
- Greaves, M.F.; Maia, A.T.; Wiemels, J.L.; Ford, A.M. Leukemia in twins: Lessons in natural history. Blood 2003, 102, 2321–2333. [Google Scholar] [CrossRef] [PubMed]
- Storey, S.; Gray, T.F.; Bryant, A.L. Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia. Curr. Geriatr. Rep. 2017, 6, 247–254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mercher, T.; Schwaller, J. Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Front. Pediatr. 2019, 7, 401. [Google Scholar] [CrossRef] [Green Version]
- Elgarten, C.W.; Aplenc, R. Pediatric acute myeloid leukemia: Updates on biology, risk stratification, and therapy. Curr. Opin. Pediatr. 2020, 32, 57–66. [Google Scholar] [CrossRef]
- Siedlecka-Kroplewska, K.; Wronska, A.; Kmiec, Z. Piceatannol, a Structural Analog of Resveratrol, Is an Apoptosis Inducer and a Multidrug Resistance Modulator in HL-60 Human Acute Myeloid Leukemia Cells. Int. J. Mol. Sci. 2021, 22, 10597. [Google Scholar] [CrossRef]
- Gibson, B.E.S.; Wheatley, K.; Hann, I.M.; Stevens, R.F.; Webb, D.; Hills, R.K.; De Graaf, S.S.N.; Harrison, C.J.; for the United Kingdom Childhood Leukaemia Working Party. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005, 19, 2130–2138. [Google Scholar] [CrossRef] [Green Version]
- Ljungman, P.; Bregni, M.; Brune, M.; Cornelissen, J.; Witte, T.d.; Dini, G.; Einsele, H.; Gaspar, H.B.; Gratwohl, A.; Passweg, J.; et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2009. Bone Marrow Transplant. 2010, 45, 219–234. [Google Scholar] [CrossRef] [Green Version]
- Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23, 1147–1157. [Google Scholar] [CrossRef]
- Levis, M. Midostaurin approved for FLT3-mutated AML. Blood 2017, 129, 3403–3406. [Google Scholar] [CrossRef] [PubMed]
- McMurry, H.; Fletcher, L.; Traer, E. IDH Inhibitors in AML—Promise and Pitfalls. Curr. Hematol. Malig. Rep. 2021, 16, 207–217. [Google Scholar] [CrossRef] [PubMed]
- Yu, B.; Liu, D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark. Res. 2019, 7, 24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wolska-Washer, A.; Robak, T. Glasdegib in the treatment of acute myeloid leukemia. Future Oncol. 2019, 15, 3219–3232. [Google Scholar] [CrossRef] [PubMed]
- Bostrom, J.; Lee, C.V.; Haber, L.; Fuh, G. Improving antibody binding affinity and specificity for therapeutic development. Methods Mol. Biol. 2009, 525, 353–376. [Google Scholar] [CrossRef] [PubMed]
- Daver, N.; Alotaibi, A.S.; Bücklein, V.; Subklewe, M. T-cell-based immunotherapy of acute myeloid leukemia: Current concepts and future developments. Leukemia 2021, 35, 1843–1863. [Google Scholar] [CrossRef]
- Maude, S.L.; Barrett, D.; Teachey, D.T.; Grupp, S.A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014, 20, 119–122. [Google Scholar] [CrossRef]
- Mardiana, S.; Gill, S. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front. Oncol. 2020, 10, 697. [Google Scholar] [CrossRef]
- Casucci, M.; Nicolis di Robilant, B.; Falcone, L.; Camisa, B.; Norelli, M.; Genovese, P.; Gentner, B.; Gullotta, F.; Ponzoni, M.; Bernardi, M.; et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013, 122, 3461–3472. [Google Scholar] [CrossRef]
- Jetani, H.; Garcia-Cadenas, I.; Nerreter, T.; Thomas, S.; Rydzek, J.; Meijide, J.B.; Bonig, H.; Herr, W.; Sierra, J.; Einsele, H.; et al. CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 2018, 32, 1168–1179. [Google Scholar] [CrossRef] [PubMed]
- Liu, F.; Cao, Y.; Pinz, K.; Ma, Y.; Wada, M.; Chen, K.; Ma, G.; Shen, J.; Tse, C.O.; Su, Y. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: Update on phase 1 clinical trial. Blood 2018, 132, 901. [Google Scholar] [CrossRef]
- Lee, D.A.; Denman, C.J.; Rondon, G.; Woodworth, G.; Chen, J.; Fisher, T.; Kaur, I.; Fernandez-Vina, M.; Cao, K.; Ciurea, S.; et al. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol. Blood Marrow Transplant. 2016, 22, 1290–1298. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.; Niu, T. Natural killer cell-based immunotherapy for acute myeloid leukemia. J. Hematol. Oncol. 2020, 13, 167. [Google Scholar] [CrossRef] [PubMed]
- Guy, D.G.; Uy, G.L. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr. Hematol. Malig. Rep. 2018, 13, 417–425. [Google Scholar] [CrossRef]
- Jitschin, R.; Saul, D.; Braun, M.; Tohumeken, S.; Völkl, S.; Kischel, R.; Lutteropp, M.; Dos Santos, C.; Mackensen, A.; Mougiakakos, D. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. J. Immunother. Cancer 2018, 6, 116. [Google Scholar] [CrossRef]
- Al-Hussaini, M.; Rettig, M.P.; Ritchey, J.K.; Karpova, D.; Uy, G.L.; Eissenberg, L.G.; Gao, F.; Eades, W.C.; Bonvini, E.; Chichili, G.R.; et al. Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform. Blood 2016, 127, 122–131. [Google Scholar] [CrossRef] [Green Version]
- Syn, N.L.; Teng, M.W.L.; Mok, T.S.K.; Soo, R.A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017, 18, e731–e741. [Google Scholar] [CrossRef]
- Acharya, N.; Sabatos-Peyton, C.; Anderson, A.C. Tim-3 finds its place in the cancer immunotherapy landscape. J. Immunother Cancer 2020, 8, e000911. [Google Scholar] [CrossRef]
- Chao, M.P.; Takimoto, C.H.; Feng, D.D.; McKenna, K.; Gip, P.; Liu, J.; Volkmer, J.P.; Weissman, I.L.; Majeti, R. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Front. Oncol. 2019, 9, 1380. [Google Scholar] [CrossRef]
- Busfield, S.J.; Biondo, M.; Wong, M.; Ramshaw, H.S.; Lee, E.M.; Ghosh, S.; Braley, H.; Panousis, C.; Roberts, A.W.; He, S.Z.; et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 2014, 28, 2213–2221. [Google Scholar] [CrossRef] [PubMed]
- Coppage, M.; Belanger, T.; Zauderer, M.; Sahasrabudhe, D. In vitro generation of tumor specific T cells that recognize a shared antigen of AML: Molecular characterization of TCR genes. Leuk. Res. 2007, 31, 195–202. [Google Scholar] [CrossRef] [PubMed]
- Van Tendeloo Viggo, F.; Van de Velde, A.; Van Driessche, A.; Cools, N.; Anguille, S.; Ladell, K.; Gostick, E.; Vermeulen, K.; Pieters, K.; Nijs, G.; et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. USA 2010, 107, 13824–13829. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qazilbash, M.H.; Wieder, E.; Thall, P.F.; Wang, X.; Rios, R.; Lu, S.; Kanodia, S.; Ruisaard, K.E.; Giralt, S.A.; Estey, E.H.; et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 2017, 31, 697–704. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marofi, F.; Rahman, H.S.; Al-Obaidi, Z.M.J.; Jalil, A.T.; Abdelbasset, W.K.; Suksatan, W.; Dorofeev, A.E.; Shomali, N.; Chartrand, M.S.; Pathak, Y.; et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Res. Ther. 2021, 12, 465. [Google Scholar] [CrossRef]
- Majzner, R.G.; Mackall, C.L. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018, 8, 1219–1226. [Google Scholar] [CrossRef] [Green Version]
- Gill, S.I. How close are we to CAR T-cell therapy for AML? Best Pract. Res. Clin. Haematol. 2019, 32, 101104. [Google Scholar] [CrossRef]
- Sterner, R.C.; Sterner, R.M. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021, 11, 69. [Google Scholar] [CrossRef]
- Guinn, B.; Greiner, J.; Schmitt, M.; Mills, K.I. Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood 2009, 113, 1203–1204. [Google Scholar] [CrossRef]
- Greiner, J.; Brown, E.; Bullinger, L.; Hills, R.K.; Morris, V.; Dohner, H.; Mills, K.I.; Guinn, B.A. Survivin’ Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients. Int. J. Mol. Sci. 2021, 22, 10482. [Google Scholar] [CrossRef]
- Davis, L.; Mills, K.I.; Orchard, K.H.; Guinn, B.A. Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia. Cancers 2020, 12, 2769. [Google Scholar] [CrossRef] [PubMed]
- Anguille, S.; Van Tendeloo, V.F.; Berneman, Z.N. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012, 26, 2186–2196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guinn, B.A.; Bland, E.A.; Lodi, U.; Liggins, A.P.; Tobal, K.; Petters, S.; Wells, J.W.; Banham, A.H.; Mufti, G.J. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem. Biophys. Res. Commun. 2005, 335, 1293–1304. [Google Scholar] [CrossRef] [PubMed]
- Adams, S.P.; Sahota, S.S.; Mijovic, A.; Czepulkowski, B.; Padua, R.A.; Mufti, G.J.; Guinn, B.A. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 2002, 16, 2238–2242. [Google Scholar] [CrossRef]
- Greiner, J.; Bullinger, L.; Guinn, B.A.; Dohner, H.; Schmitt, M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin. Cancer Res. 2008, 14, 7161–7166. [Google Scholar] [CrossRef] [Green Version]
- Hardwick, N.; Buchan, S.; Ingram, W.; Khan, G.; Vittes, G.; Rice, J.; Pulford, K.; Mufti, G.; Stevenson, F.; Guinn, B.A. An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immun. 2013, 13, 16. [Google Scholar]
- Greiner, J.; Gotz, M.; Wais, V. Increasing Role of Targeted Immunotherapies in the Treatment of AML. Int. J. Mol. Sci. 2022, 23, 3304. [Google Scholar] [CrossRef]
- Hindley, A.; Catherwood, M.A.; McMullin, M.F.; Mills, K.I. Significance of NPM1 Gene Mutations in AML. Int. J. Mol. Sci. 2021, 22, 10040. [Google Scholar] [CrossRef]
- Dohner, H.; Estey, E.; Grimwade, D.; Amadori, S.; Appelbaum, F.R.; Buchner, T.; Dombret, H.; Ebert, B.L.; Fenaux, P.; Larson, R.A.; et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017, 129, 424–447. [Google Scholar] [CrossRef] [Green Version]
- Venney, D.; Mohd-Sarip, A.; Mills, K.I. The Impact of Epigenetic Modifications in Myeloid Malignancies. Int. J. Mol. Sci. 2021, 22, 5013. [Google Scholar] [CrossRef]
- Barresi, V.; Di Bella, V.; Andriano, N.; Privitera, A.P.; Bonaccorso, P.; La Rosa, M.; Iachelli, V.; Spampinato, G.; Pulvirenti, G.; Scuderi, C.; et al. NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia. Int. J. Mol. Sci. 2021, 22, 4575. [Google Scholar] [CrossRef] [PubMed]
- Cairns, L.V.; Lappin, K.M.; Mutch, A.; Ali, A.; Matchett, K.B.; Mills, K.I. Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia. Int. J. Mol. Sci. 2021, 22, 10163. [Google Scholar] [CrossRef]
- Gorombei, P.; Guidez, F.; Ganesan, S.; Chiquet, M.; Pellagatti, A.; Goursaud, L.; Tekin, N.; Beurlet, S.; Patel, S.; Guerenne, L.; et al. BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. Int. J. Mol. Sci. 2021, 22, 10658. [Google Scholar] [CrossRef] [PubMed]
- Greenberg, P.L.; Tuechler, H.; Schanz, J.; Sanz, G.; Garcia-Manero, G.; Sole, F.; Bennett, J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F.; et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120, 2454–2465. [Google Scholar] [CrossRef]
- Omidvar, N.; Kogan, S.; Beurlet, S.; le Pogam, C.; Janin, A.; West, R.; Noguera, M.E.; Reboul, M.; Soulie, A.; Leboeuf, C.; et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res. 2007, 67, 11657–11667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brown, E.; Guinn, B.-a. Molecular Mechanisms and Therapies of Myeloid Leukaemia. Int. J. Mol. Sci. 2022, 23, 6251. https://doi.org/10.3390/ijms23116251
Brown E, Guinn B-a. Molecular Mechanisms and Therapies of Myeloid Leukaemia. International Journal of Molecular Sciences. 2022; 23(11):6251. https://doi.org/10.3390/ijms23116251
Chicago/Turabian StyleBrown, Elliott, and Barbara-ann Guinn. 2022. "Molecular Mechanisms and Therapies of Myeloid Leukaemia" International Journal of Molecular Sciences 23, no. 11: 6251. https://doi.org/10.3390/ijms23116251